CoraVie Medical CEO Aimee Garza and Dr. Michael Bloch, a hypertension specialist and clinical advisor for the startup, talk about why the healthcare industry needs a better approach to blood pressure ...

Cadence raised $100 million in Series C funding to scale its AI-powered chronic care platform, which monitors patients at ...

A partition at the UnitedHealthcare headquarters building in Eden Prairie, Minnesota On Thursday, I was among roughly 15 journalists, influencers and industry analysts invited to the headquarters of ...

Nadia Care raised $12 million in funding to expand its community-centered maternal care, the startup announced on Monday. The maternal health company is formerly known as Cayaba Care and offers care ...

The case that many startups are making for automating the healthcare revenue cycle is pretty straightforward. Claims follow rules, payers adhere to guidelines, and most of this work is repetitive ...

Healthcare isn’t struggling to adopt AI. In fact, the industry has moved quickly from early experimentation to widespread investment in tools designed to improve clinical decision-making, reduce ...

Ladder Health, a virtual-first pediatric developmental care startup, announced on Tuesday that it secured $7 million in seed funding to expand into new markets. Boston-based Ladder Health supports ...

Women wait an average of seven to ten years to be diagnosed with endometriosis. For PMOS, fibroids, perimenopause and dozens of other conditions, the story is similar, typically involving dismissed ...

The FDA now agrees uniQure’s clinical data for its Huntington’s disease gene therapy can support a regulatory submission in this rare neurodegenerative disorder, reversing its stance just a few months ...

On February 23, the FDA did something the rare disease community has spent a decade fighting for: it issued the Plausible Mechanism Framework, a formal pathway for individualized therapies where ...

New federal attention to psychedelic research and a major Texas-funded clinical trial initiative are moving compounds like ibogaine from the margins of substance use disorder (SUD) treatment debate ...